2016
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research 2016, 22: 374-382. PMID: 26307133, PMCID: PMC4821426, DOI: 10.1158/1078-0432.ccr-15-1162.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDisease-Free SurvivalDNA Copy Number VariationsDNA Mutational AnalysisDouble-Blind MethodGenes, rasHumansMelanomaMutationNeoplasm StagingNiacinamidePaclitaxelPhenylurea CompoundsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-metSorafenibTreatment OutcomeConceptsProgression-free survivalGene copy gainOverall survivalImproved progression-free survivalCopy gainImproved overall survivalGenomic alterationsCancer Genome Atlas (TCGA) datasetImproved treatment responseClinical outcomesMET amplificationV600KCCND1 amplificationTreatment responseMelanoma pathogenesisV600E mutationCurrent FDAPretreatment samplesBRAF geneTumor samplesPatientsSorafenibTherapyTumorsAtlas dataset
2013
Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM. Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLOS ONE 2013, 8: e69748. PMID: 23936348, PMCID: PMC3735539, DOI: 10.1371/journal.pone.0069748.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalVEGF-R1FGF-R1Paclitaxel-based therapyVEGF-R1 expressionPre-treatment tumorsPredictive biomarker signaturesMultitarget kinase inhibitorPDGF-RβSitu protein expressionTherapeutic ratioTaxane sensitivityMitogen-activated protein kinase pathwayPatientsVEGF-R3CarboplatinSorafenibVEGF-R2C-kitKinase inhibitorsTherapyProtein expressionPhase IIISorafenib targets